No Data
Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) CEO Fei Gao, the Company's Largest Shareholder Sees 7.7% Reduction in Holdings Value
Aotai Biotech: Third quarter report 2024
Third Quarter Report 2024
Aotec Biology (688606.SH) released its performance for the first three quarters, with net income of 0.198 billion yuan, a year-on-year increase of 94.48%.
Aotec Pharmaceuticals (688606.SH) disclosed the third quarter report for 2024, achieving revenue of 6....
Otaix Biotech (688606.SH): The proposed mid-term profit distribution for 2024 is a dividend of 15 yuan per 10 shares.
On September 19th, GeLongHui (688606.SH) announced the mid-term profit distribution plan for 2024, stating that the company plans to distribute a cash dividend of 15 yuan (including taxes) per 10 shares to all shareholders.
Otaibio (688606.SH): will use the remaining raised funds of 38.9807 million yuan to permanently supplement working capital.
On September 19th, GTJA announced that in order to better utilize the raised funds and improve the efficiency of fund usage, the company plans to close the project "Construction of an annual production of 0.2 billion human diagnostic reagents production center and research center" and permanently supplement the remaining raised funds of 38.9807 million yuan (including interest income and financial management income after deducting fees, the actual amount is subject to the balance in the special account on the day of fund transfer) as working capital for daily production and operation activities. After the transfer of the remaining raised funds, the company will handle the account closure procedures and cancel the relevant raised fund accounts as required.
Is Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Stock Price Struggling As A Result Of Its Mixed Financials?